Laboratory and animal research, especially in NSCLC models, has consistently demonstrated that pioglitazone, through its activity as a PPARγ agonist, can slow tumor growth, promote cell differentiation, and even prevent progression of early-stage lesions. Here, PPARG is linked to non-small cell lung carcinoma.